Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | FRK | P42685 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | STK3 | Q13188 | 1/20 | 0.53 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.53 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852742 | 0.89 | CSF1R (0.75) | CSF1RKDM4E | |
| SCHEMBL4842478 | 0.88 | CSF1R (0.69) | CSF1RKDM4EROCK2MAP4K4LCK | |
| SCHEMBL4850716 | 0.85 | CSF1R (0.74) | CSF1RKDM4EROCK2MAP4K4LCK | |
| SCHEMBL4844934 | 0.84 | CSF1R (1.00) | CSF1R | |
| SCHEMBL4850849 | 0.84 | CSF1R (1.00) | CSF1RKDM4EROCK2MAP4K4LCK | |
| SCHEMBL4851197 | 0.83 | CSF1R (0.66) | CSF1RKDM4EROCK2MAP4K4LCK | |
| SCHEMBL4849483 | 0.83 | CSF1R (0.65) | CSF1RKDM4EMAPT | |
| SCHEMBL14293964 | 0.83 | CSF1R (0.65) | CSF1RKDM4E | |
| SCHEMBL4853377 | 0.82 | CSF1R (0.96) | CSF1R | |
| SCHEMBL4849655 | 0.82 | CSF1R (0.73) | CSF1RKDM4EROCK2MAP4K4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | claimed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | claimed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | claimed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | CSF1R 192/4885KDM4E 1118/4885ROCK2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.